We found that the inhibition of the CBP/β-catenin axis mediated by ICG-001 in oral squamous cell carcinoma led to the downregulation of BIRC5, EZH2, AURKA, CCNA2, and other genes previously implicated in therapy resistance (Figure 5D). This evidence concerns the gene EZH2 and oral cavity squamous cell carcinoma.